What is the history of Sweet Syndrome?

Sweet Syndrome, also known as acute febrile neutrophilic dermatosis, was first described in 1964 by Dr. Robert Douglas Sweet, who identified the condition in eight women presenting with fever and tender, erythematous skin plaques. While initial reports focused on the dermatological presentation, medical understanding has evolved to recognize Sweet Syndrome as a systemic inflammatory disorder often linked to underlying malignancies, infections, or medications.

When was Sweet Syndrome first described?

The history of Sweet Syndrome began in 1964 when Dr. Robert Douglas Sweet, a British dermatologist, published his seminal paper in the British Journal of Dermatology. He characterized the disorder through clinical observations of patients experiencing fever, neutrophilia, and characteristic skin lesions. Since that initial discovery, the medical community has expanded the diagnostic criteria to include both classical and malignancy-associated forms of Sweet Syndrome.

How has our understanding of the condition evolved?

Early researchers initially struggled to distinguish Sweet Syndrome from infectious skin conditions. Over time, advancements in histopathology allowed clinicians to identify the hallmark infiltration of mature neutrophils in the upper dermis. Modern diagnostic criteria, refined by Su and Liu in 1986, remain the gold standard for clinicians today, helping to separate Sweet Syndrome from other neutrophilic dermatoses.

What are the major milestones in treatment?

The management of Sweet Syndrome has shifted significantly as our understanding of its inflammatory nature improved:

• 1970s: Systemic corticosteroids were established as the first-line therapy to rapidly reduce inflammation.


• 1990s: Potassium iodide and colchicine emerged as effective steroid-sparing alternatives.


• Modern Era: Targeted biologic therapies, such as IL-1 receptor antagonists, are now utilized for recalcitrant cases of Sweet Syndrome.

How has patient advocacy changed the landscape?

For decades, Sweet Syndrome was considered a rare, isolated skin issue. Today, patient advocacy groups and platforms like DiseaseMaps.org have empowered the 73 community members currently registered to share their experiences. This collective data helps bridge the gap between rare clinical case reports and the lived reality of patients, fostering global awareness and faster diagnostic timelines.

Next steps

• Consult with a board-certified dermatologist or rheumatologist for accurate diagnostic assessment.


• Join the Sweet Syndrome community on DiseaseMaps.org to connect with others and share experiences.


• Request a referral to a center of excellence if your case is refractory to standard corticosteroid treatment.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Sweet Syndrome overview.


• Orphanet: Acute febrile neutrophilic dermatosis (ORPHA:3249).


• PubMed: Original 1964 description by R.D. Sweet.


• OMIM: Entry for Sweet Syndrome (MIM #608068).